| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Ji, Xuemei, et al.
(författare)
-
Protein-altering germline mutations implicate novel genes related to lung cancer development
- 2020
-
Ingår i: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 11:1
-
Tidskriftsartikel (refereegranskat)abstract
- Few germline mutations are known to affect lung cancer risk. We performed analyses of rare variants from 39,146 individuals of European ancestry and investigated gene expression levels in 7,773 samples. We find a large-effect association with an ATM L2307F (rs56009889) mutation in adenocarcinoma for discovery (adjusted Odds Ratio=8.82, P=1.18x10(-15)) and replication (adjusted OR=2.93, P=2.22x10(-3)) that is more pronounced in females (adjusted OR=6.81 and 3.19 and for discovery and replication). We observe an excess loss of heterozygosity in lung tumors among ATM L2307F allele carriers. L2307F is more frequent (4%) among Ashkenazi Jewish populations. We also observe an association in discovery (adjusted OR=2.61, P=7.98x10(-22)) and replication datasets (adjusted OR=1.55, P=0.06) with a loss-of-function mutation, Q4X (rs150665432) of an uncharacterized gene, KIAA0930. Our findings implicate germline genetic variants in ATM with lung cancer susceptibility and suggest KIAA0930 as a novel candidate gene for lung cancer risk. In lung cancer, relatively few germline mutations are known to impact risk. Here the authors looked at rare variants in 39,146 individuals and find novel germline mutations associated with risk, as well as implicating ATM and a new candidate gene for lung cancer risk.
|
|
| 5. |
|
|
| 6. |
- Bechta, Sevostian, et al.
(författare)
-
Phase diagram of the UO2-FeO1+x system
- 2007
-
Ingår i: Journal of Nuclear Materials. - : Elsevier BV. - 0022-3115 .- 1873-4820. ; 362:1, s. 46-52
-
Tidskriftsartikel (refereegranskat)abstract
- Phase-relation studies of the UO2–FeO1+x system in an inert atmosphere are presented. The eutectic point has beendetermined, which corresponds to a temperature of (1335 ± 5) C and a UO2 concentration of (4.0 ± 0.1) mol.%. Themaximum solubility of FeO in UO2 at the eutectic temperature has been estimated as (17.0 ± 1.0) mol.%. Liquidus temperaturesfor a wide concentration range have been determined and a phase diagram of the system has been constructed.
|
|
| 7. |
- Bechta, Sevostian, et al.
(författare)
-
Phase diagram of the ZrO2-FeO system
- 2006
-
Ingår i: Journal of Nuclear Materials. - : Elsevier BV. - 0022-3115 .- 1873-4820. ; 348:1-2, s. 114-121
-
Tidskriftsartikel (refereegranskat)abstract
- The results on the ZrO2–FeO system studies in a neutral atmosphere are presented. The refined eutectic point has beenfound to correspond to a ZrO2 concentration of 10.3 ± 0.6 mol% at 1332 ± 5 C. The ultimate solubility of iron oxide inzirconia has been determined in a broad temperature range, taking into account the ZrO2 polymorphism. A phase diagramof the pseudobinary system in question has been constructed.
|
|
| 8. |
- Bechta, Sevostian, et al.
(författare)
-
Phase transformation in the binary section of the UO2-FeO-Fe system
- 2007
-
Ingår i: Radiochemistry (New York, N.Y.). - 1066-3622 .- 1608-3288. ; 49:1, s. 20-24
-
Tidskriftsartikel (refereegranskat)abstract
- Phase transformations in the oxide binary section of the UO2-FeO-Fe ternary system were studied. The melting onset point of the UO2-FeO heterogeneous system (1335±5°C) was determined and the fusion curve of this system was constructed. The limiting solubility of FeO in the UO2 solid solution was measured. The changes in crystal parameters in formation of the solid solution were determined. Uranium dioxide was found to be insoluble in the wüstite phase (FeO).
|
|
| 9. |
- Dencker, Lennart, et al.
(författare)
-
Position Paper : EUFEPS Network on Veterinary Medicines Initiative: An interdisciplinary forum to support Veterinary Pharmacology and promote the development of new pharmaceuticals for Animal Health
- 2016
-
Ingår i: European Journal of Pharmaceutical Sciences. - 0928-0987 .- 1879-0720. ; 91, s. I-VII
-
Tidskriftsartikel (refereegranskat)abstract
- Veterinary medicines account for a substantial portion of the production, sale, and consumption of medicines in Europe, and probably world-wide. This calls our attention to the fact that only healthy farm animals can ensure safe and sufficient livestock products to meet the growing demand for animal protein. Human and veterinary medicine share many common features - expressed and symbolised by the "One Health Concept". This concept forms the logical basis for the maintenance of healthy livestock by the control of zoonoses and foodborne diseases, the prevention of poor sanitary conditions, and the reduction of microbial and parasitic threats, including resistance to antibiotics and anti-parasitic drugs. Achieving these aims will require international cooperation and interdisciplinary action. A new initiative of the European Federation for Pharmaceutical Sciences (EUFEPS) - the Network on Veterinary Medicines - has the potential to manage and overcome these challenges. A number of EUFEPS expertise networks have already been established, and some will be instrumental in supporting the activities of the Network on Veterinary Medicines, e.g., the European Network on PharmacoGenomics Research and Implementation (EPRIN), as well as the Network on Bioavailability and Biopharmaceutics, and the envisioned Network on Systems Pharmacology. Notably, the EUFEPS Networks on Safety Sciences, on Environment and Pharmaceuticals and on NanoMedicine as well as on Regulatory Science, represent promising partners. New technologies are being introduced to veterinary medicine for the treatment of numerous and frequently species-specific conditions. Scientific input from different areas is required to evaluate the potential benefitrisk profiles of these novel products, drug delivery techniques, and medical attention for animals as a whole. Drug treatment of food-producing animals inevitably affects consumer safety and public health, as any administration of medicines to animals may result in the presence of drug residues in edible tissues or products such as milk, eggs, and honey. The many questions surrounding the risks to human health and to the environment posed by exposure to veterinary drug residues cause great concern among health authorities as well as the public. In particular, the shared use of many classes of antimicrobials in both veterinary and human medicine, the emergence and spread of resistant microbes from animals or animal-derived products to humans, and the presence of contaminated manure in the environment are all provoking deep concern throughout the world. The Network on Veterinary Medicines initiative sees itself as broadly positioned. Among its most important goals are contributing to legislative issues in veterinary medicine and to the development of new pharmaceuticals for animal health, including novel drug delivery systems. Efforts to support the academic teaching and training of veterinary professionals and formulators for veterinary drug delivery are also considered imperative objectives of the network. The pursuit of these tasks will depend on interdisciplinary cooperation among experts from pharmaceutical and veterinary sciences, concentrating on issues where scientists from academia, industry and regulatory agencies can collaborate. National and international healthcare bodies, as well as organisations dedicated to the endorsement of teaching and training of scientists in pharmaceutical and veterinary sciences, are also key partners. Major objectives of the network include the following: strengthening academic research to promote the emergence of new concepts, principles and mechanisms of action to develop innovative new veterinary medicinal products, supporting the education and training of future healthcare professionals in veterinary practice, pharmacy and industrial research, including continuing professional development, and supporting Veterinary Universities. Further efforts of the Network will encourage the European Commission to initiate calls for research in the area of veterinary medicines, such as Horizon 2020. Once these calls are in place, the formation of strong consortia to apply for funding (IMI, EU-funding) is projected. The success of the Network depends on the engagement and expertise of cooperating specialists. It will benefit from the experience and means of other EUFEPS networks.
|
|
| 10. |
- Hellmann, S., et al.
(författare)
-
Time-resolved x-ray photoelectron spectroscopy at FLASH
- 2012
-
Ingår i: New Journal of Physics. - : IOP Publishing. - 1367-2630. ; 14
-
Tidskriftsartikel (refereegranskat)abstract
- The technique of time-resolved pump-probe x-ray photoelectron spectroscopy using the free-electron laser in Hamburg (FLASH) is described in detail. Particular foci lie on the macrobunch resolving detection scheme, the role of vacuum space-charge effects and the synchronization of pump and probe lasers. In an exemplary case study, the complete Ta 4f core-level dynamics in the layered charge-density-wave (CDW) compound 1T-TaS2 in response to impulsive optical excitation is measured on the sub-picosecond to nanosecond timescale. The observed multi-component dynamics is related to the intrinsic melting and reformation of the CDW as well as to extrinsic pump-laser-induced vacuum space-charge effects.
|
|
